Natera to work with Exelixis on latter's zanzalintinib phase 3 trial
Source: SeekingAlpha
2026-01-07 09:14:28 ET
More on Exelixis, Natera
- Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day - Slideshow
- Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript
- Why Natera Remains A 'Hold' For Me Despite Surging MRD Growth And Fatter Margins
- Exelixis cut to Underperform at BofA on valuation and lack of catalysts
- LLY joins $1T club but doesn't feature in SA's top 10 large-cap healthcare stocks
Read the full article on Seeking Alpha
For further details see:
Natera to work with Exelixis on latter's zanzalintinib phase 3 trial
Exelixis Inc.
NASDAQ: EXEL
EXEL Trading
0.07% G/L:
$40.86 Last:
740,799 Volume:
$41.665 Open:
EXEL Latest News
February 28, 2026 04:57:00 am
3 Reasons Exelixis Stock Could Deliver Market?Beating Returns Over the Next Decade
February 24, 2026 04:05:00 pm
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March
February 24, 2026 10:58:00 am
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge
February 20, 2026 04:05:00 pm
Exelixis: The Cash?Generating Biotech That I Think Deserves a Closer Look in 2026
EXEL Stock Data
$11,614,618,641
260,551,394
1.54%
313
N/A
Biotechnology & Life Sciences
Healthcare
US
Alameda
